<?xml version="1.0" encoding="utf-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
>

<channel rdf:about="http://www.biochemj.org">
<title>BJ Gene Immediate Publications</title>
<link>http://www.biochemj.org</link>
<description>Biochemical Journal RSS feed -- BJ Gene Immediate Publications</description>
<prism:issn>0264-6021</prism:issn>
<prism:eIssn>1470-8728</prism:eIssn>
<prism:publicationName>Biochemical Journal</prism:publicationName>
<items>
 <rdf:Seq>
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111925" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111584" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111645" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111052" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111801" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111856" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111748" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111817" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111648" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111768" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111284" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111739" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111502" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111745" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111322" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111271" />
	<rdf:li rdf:resource="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111517" />
	
	 </rdf:Seq>
</items>
<image rdf:resource="http://www.biochemj.org/images/BJ_Name.gif" />
</channel>

<image rdf:about="http://www.biochemj.org/images/BJ_Name.gif">
<title>Biochemical Journal</title>
<url>http://www.biochemj.org/images/BJ_Name.gif</url>
<link>http://www.biochemj.org</link>
</image>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111925">
	<title><![CDATA[A naturally occurring nonapeptide functionally compensates the CP1 domain of leucyl-tRNA synthetase to modulate aminoacylation activity]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111925</link>
	<description><![CDATA[Aminoacyl-tRNA synthetases (aaRSs) establish the rules of the genetic code by catalyzing the formation of aminoacyl-tRNA. The quality control for aminoacylation reaction is achieved by editing activity, which is usually carried out by a discrete editing domain. For leucyl-tRNA synthetase (LeuRS), the connective peptide 1 (CP1) domain is the editing domain responsible for hydrolyzing mis-charged tRNA. The CP1 domain is universally present in LeuRSs except LeuRS from <i>Mycoplasma mobile</i> (<i>Mm</i>LeuRS). The substitute of CP1 in <i>Mm</i>LeuRS is a nonapeptide (<i>Mm</i>Linker). We show here that the <i>Mm</i>Linker, which is critical for aminoacylation activity of <i>Mm</i>LeuRS, could confer remarkable tRNA charging activity to the inactive CP1-deleted LeuRS from <i>Escherichia coli</i> (<i>Ec</i>LeuRS) and <i>Aquifex aeolicus</i> (<i>Aa</i>LeuRS). Furthermore, CP1 from <i>Ec</i>LeuRS could functionally compensate the <i>Mm</i>Linker and endow <i>Mm</i>LeuRS with post-transfer editing capability. These investigations provide a mechanistic framework for the modular construction of aaRSs and their coordination to achieve catalytic efficiency and fidelity. These results also show that the pre-transfer editing function of LeuRS originates from its conserved synthetic domain, and shed light on future mechanism study.]]></description>
	<dc:creator>M Tan, W Yan, R Liu, M Wang, X Chen, X Zhou, E Wang</dc:creator>
	<dc:date>2012-02-01T11:52:02Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111925</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-02-01</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111584">
	<title><![CDATA[Cross-talk between TGF{beta}1 and EGFR signaling pathways induces TM4SF5 expression and Epithelial-Mesenchymal Transition]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111584</link>
	<description><![CDATA[The epithelial-mesenchymal transition (EMT) is involved in fibrosis and cancer, and regulated by different signaling pathways mediated through soluble factors, actin reorganization, and transcription factor actions. Because tetraspan(in) transmembrane 4 L6 family member 5 (TM4SF5) is highly expressed in hepatocellular carcinoma and induces EMT, understanding how TM4SF5 expression in hepatocytes is regulated is important. We explored the mechanisms that induce TM4SF5 expression and whether impaired signaling pathways for TM4SF5 expression inhibit acquisition of mesenchymal cell features, using human and mouse normal hepatocytes. We found that transforming growth factor beta 1 (TGF&#x03B2;1)-mediated Smad activation caused TM4SF5 expression and EMT, and activation of the epidermal growth factor receptor (EGFR) pathway. Inhibition of EGFR activity following TGF&#x03B2;1 treatment abolished acquisition of EMT, suggesting a link from Smads to EGFR for TM4SF5 expression. Further, TGF&#x03B2;1-mediated EGFR activation and TM4SF5 expression were abolished by EGFR suppression or extracellular EGF depletion. Smad overexpression mediated EGFR activation and TM4SF5 expression in the absence of serum, and EGFR kinase inactivation or EGF depletion abolished Smad overexpression-induced TM4SF5 and mesenchymal cell marker expression. Inhibition of Smad, EGFR, or TM4SF5 using Smad7 or small compounds also blocked TM4SF5 expression and/or EMT. These results indicate that TGF&#x03B2;1- and growth factor-mediated signaling activities mediate TM4SF5 expression leading to acquisition of mesenchymal cell features, suggesting that TM4SF5 induction may be involved in development of liver pathologies.]]></description>
	<dc:creator>M Kang, S Choi, S Jeong, S Lee, T Kwak, H Kim, O Jung, M Lee, Y Ko, J Ryu, Y Choi, D Jeong, H Lee, S Ye, S Kim, J Lee</dc:creator>
	<dc:date>2012-01-31T14:13:54Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111584</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-31</prism:publicationDate>
	<prism:section>BJ Signal</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111645">
	<title><![CDATA[The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111645</link>
	<description><![CDATA[PCSK9 (proprotein convertase subtilisin/kexin type 9 ) plays an important role in control of plasma LDL cholesterol metabolism by modulating the degradation of hepatic LDL receptor. Previous studies demonstrated that PCSK9 is a target gene of the sterol regulatory element (SRE) binding protein 2 (SREBP2) that activates PCSK9 gene transcription through an SRE motif of the promoter. In addition to SREBP2, hepatic nuclear factor 1a (HNF1a) positively regulates PCSK9 gene transcription in hepatic cells through a binding site located 28 bp upstream from SRE. In this study, we have identified a novel histone nuclear factor P (HINFP) recognition motif residing between HNF1 motif and SRE that is essential for basal and sterol-regulated transcriptions of the PCSK9 promoter. Mutation of this motif lowers the basal promoter activity and abolishes the sterol-mediated repression as well as the SREBP2-induced activation of the PCSK9 promoter. We further show that the activity of SREBP2 in stimulating PCSK9 promoter activity is greatly enhanced by HINFP. Additional experiments suggest that HINFP and its cofactor NPAT form a functional complex, and NPAT may subsequently recruit HAT cofactor TRRAP to facilitate the histone H4 acetylation of the PCSK9 promoter. Knockdown of HINFP, NPAT or TRRAP each markedly reduces the amount of acetylated histone H4 on the PCSK9 promoter region and lowers PCSK9 protein levels. Importantly, by utilizing co-immunoprecipitation assays, we have demonstrated a direct interaction between SREBP2 and HINFP and its cofactor NPAT/TRRAP. These new findings, altogether, identify HINFP as a co-activator in SREBP-mediated transactivation of PCSK9 gene expression.]]></description>
	<dc:creator>H Li, J Liu</dc:creator>
	<dc:date>2012-01-31T12:11:41Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111645</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-31</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111052">
	<title><![CDATA[Involvement of PGE2 and cyclic AMP signaling pathway in the up-regulation of COX-2 and mPGES-1 expression in LPS -activated macrophages]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111052</link>
	<description><![CDATA[Prostaglandin (PG) E<sub>2</sub> plays an important role in the modulation of the immune response and the inflammatory process. In this study, we describe a PGE<sub>2 </sub>positive feedback for Cyclooxygenase (COX) -2 and microsomal PGE Synthase (mPGES) -1 expression in the macrophage cell line RAW 264.7. Our results show that PGE<sub>2 </sub>induces COX-2 and mPGES-1 expression, an effect mimicked by dibutyryl-cAMP (dbcAMP) or Forskolin. Furthermore, cAMP signaling pathway cooperates with LPS in the induction of COX-2 and mPGES-1 transcriptional activation. Analysis of the involvement of EP receptors showed that incubation with EP2 agonists up-regulated both COX-2 and mPGES-1 mRNA levels. Moreover, EP2 receptor over expression enhanced the transcriptional activation of COX-2 and mPGES-1 promoters, being this induction abolished by the PKA inhibitor, H89. Activation of PGE<sub>2</sub>/EP2/PKA signaling pathway induced the phosphorylation of the cAMP response element-binding protein (CREB) in macrophages and stimulated the specific binding of this transcription factor to COX-2 and mPGES-1 promoters. Deletion or mutation of potential CRE sites in both promoters diminished their transcriptional activity. In summary, our data demonstrate that activation of PKA/CREB signaling through the EP2 receptor by PGE<sub>2</sub> plays a key role in the expression of COX-2 and mPGES-1 in activated macrophages.]]></description>
	<dc:creator>M D. D&#x00ED;az-Mu&#x00F1;oz, I C. Osma-Garc&#x00ED;a, M Fresno, M A. I&#x00F1;iguez</dc:creator>
	<dc:date>2012-01-23T14:40:59Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111052</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-23</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111801">
	<title><![CDATA[Regulation of Human Microsomal Prostaglandin E Synthase-1 by IL-1{beta} requires a Distal Enhancer Element with a Unique Role for C/EBP{beta}]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111801</link>
	<description><![CDATA[The studies of prostaglandin E2 (PGE<sub>2</sub>) biosynthesis have primarily focused on the role of cyclooxygenases. Efforts have shifted towards the specific PGE<sub>2</sub> terminal synthases, particularly microsomal PGE synthase (mPGES-1), which has emerged as the crucial inducible synthase with roles in pain, cancer and inflammation. mPGES-1 is induced by proinflammatory cytokines with studies focusing on the proximal promoter, mediated specifically through Egr-1. Numerous studies demonstrate that the mPGES-1 promoter alone cannot account for the level of IL-1&#x03B2; induction. We identified two DNase I hypersensitive sites within the proximal promoter near the Egr-1 element and a novel distal site near -8.6kb. Functional analysis of the distal site revealed two elements that cooperate with basal promoter expression and a stimulus-dependent enhancer. A specific binding site for CCAAT/enhancer binding protein beta (C/EBP&#x03B2;) in the enhancer was directly responsible for inducible enhancer activity. ChIP analysis demonstrated constitutive Egr-1 binding to the promoter and induced RNA polymerase II and C/EBP&#x03B2; binding to the promoter and enhancer, respectively. Knockout/knockdown studies established a functional role for C/EBP&#x03B2; in mPGES-1 gene regulation and documented interaction between Egr-1 and C/EBP&#x03B2; highlights the proximal promoter cooperation with a novel distal enhancer element in regulating inducible mPGES-1 expression.]]></description>
	<dc:creator>J N Walters, J S Bickford, K J Newsom, D E Beachy, S J Barilovits, J Herlihy, H S Nick</dc:creator>
	<dc:date>2012-01-20T12:25:53Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111801</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-20</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111856">
	<title><![CDATA[Transcriptional regulation mechanisms of Hypoxia-induced neuroglobin gene expression]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111856</link>
	<description><![CDATA[Neuroglobin (Ngb) has been identified as a novel endogenous neuroprotectant. However, little is known about the regulation mechanisms of Ngb expression, especially under hypoxia conditions. In this study, we located the core proximal promoter of mouse Ngb gene to a 554 bp segment, which harbors putative conserved NF&#x03BA;B, Egr1 binding sites. Over-expression and knock-down of transcription factors p65, p50, Egr1 or Sp1 increased and decreased Ngb expression, respectively. Experimental assessments with transfections of mutational Ngb gene promoter constructs, as well as EMSA and ChIP assays demonstrated that NF&#x03BA;B family members (p65, p50, cRel), Egr1, and Sp1 bound <i>in vitro </i>and <i>in vivo</i> to the proximal promoter region of Ngb gene. Moreover, a &#x03BA;B3 site was found as a pivotal <i>cis</i>-element responsible for hypoxia-induced Ngb promoter activity. NF&#x03BA;B (p65) and Sp1 were also responsible for hypoxia-induced upregulation of Ngb expression. Although there are no conserved HREs (hypoxia-response elements) in the promoter of mouse Ngb gene, our results suggested that HIF1&#x03B1; is also involved in hypoxia-induced Ngb upregulation. In conclusion, we identified that NF&#x03BA;B, Egr1, and Sp1 played important roles in regulation of basal Ngb expression via specific interactions with the mouse Ngb promoter. NF&#x03BA;B, Sp1 and HIF1&#x03B1; contributed to the upregulation of mouse Ngb gene expression under hypoxic conditions.]]></description>
	<dc:creator>N liu, Z Yu, S Xiang, S Zhao, A Tj&#x00E4;rnlund Wolf, C Xing, J Zhang, X Wang</dc:creator>
	<dc:date>2012-01-13T11:45:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111856</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-13</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111748">
	<title><![CDATA[Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation.]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111748</link>
	<description><![CDATA[Nutrient deprivation or starvation frequently correlates with amino acid limitation. Amino acid starvation initiates a signal transduction cascade starting with the activation of the kinase GCN2 phosphorylation of eukaryotic initiation factor 2, global protein synthesis reduction and increased activating transcription factor (ATF) 4. ATF4 modulates a wide spectrum of genes involved in the adaptation to dietary stress. The hormone FGF21 is induced during fasting in liver, and its expression induces a metabolic state that mimics long-term fasting. Thus, FGF21 is critical for the induction of hepatic fat oxidation, ketogenesis and gluconeogenesis, metabolic processes which are essential for the adaptive metabolic response to starvation. In this article, we show that FGF21 is induced by amino acid deprivation in both mouse liver and HepG2 cultured cells. We have identified the human <i>FGF21</i> gene as a target gene for ATF4 and we have localized two conserved ATF4 binding sequences in the 5&#x2019; regulatory region of the human <i>FGF21</i> gene, which are responsible for the ATF4-dependent transcriptional activation of this gene. These results add <i>FGF21</i> gene induction to the transcriptional program initiated by increased levels of ATF4 and offer a new mechanism for the induction of the <i>FGF21</i> gene expression under nutrient deprivation.]]></description>
	<dc:creator>A De Sousa-Coelho, P F. Marrero, D Haro</dc:creator>
	<dc:date>2012-01-11T12:04:15Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111748</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-11</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111817">
	<title><![CDATA[Serum Copper as a Novel Biomarker for Resistance to Thyroid Hormone]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111817</link>
	<description><![CDATA[Thyroid hormone action is mediated by the thyroid hormone receptors TRa1 and TRb. Defects in TRb lead to &#x201C;Resistance to Thyroid Hormone&#x201D; (RTHb), a syndrome characterized by high levels of thyroid hormone and non-suppressed thyroid-stimulating hormone (TSH). However, a correct diagnosis of RTHb patients is difficult as the clinical picture varies. A biochemical serum marker indicative of defects in TRb signaling is needed and could simplify the diagnosis of RTHb, in particular the differentiation to TSH-secreting pituitary adenomas, which present with clinically similar symptoms. 
 Here we show that serum copper levels are regulated by thyroid hormone, which stimulates the synthesis and the export of the hepatic Cu-transport protein ceruloplasmin into the serum. This is accompanied by a concerted reduction of the mRNA levels of other Cu-containing proteins such as metallothioneins 1 and 2 or superoxide dismutase 1. The induction of serum Cu was abolished in genetically hyperthyroid mice lacking TRb and human RTHb patients, demonstrating an important role of TRb for this process. Together with a previously reported TRa1 specific regulation of serum selenium, we furthermore show that the ratio of serum Cu and Se &#x2013; which is largely independent of thyroid hormone levels, volume changes or sample degradation &#x2013; can constitute a valuable novel biomarker for RTHb. Moreover, it could also provide a suitable large-scale screening parameter to identify RTHa patients, which have not been identified to date.]]></description>
	<dc:creator>J Mittag, T Behrends, K Nordstr&#x00F6;m, J Anselmo, B Vennstr&#x00F6;m, L Schomburg</dc:creator>
	<dc:date>2012-01-06T11:15:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111817</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2012-01-06</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111648">
	<title><![CDATA[Transcriptional control of glyoxalase 1 by Nrf2 provides a stress responsive defence against dicarbonyl glycation]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111648</link>
	<description><![CDATA[Abnormal cellular accumulation of the dicarbonyl metabolite methylglyoxal occurs on exposure to high glucose concentration, inflammation, cell ageing and senescence. It is associated with increased methylglyoxal-adduct content of protein and DNA linked to increased DNA strand breaks and mutagenesis, mitochondrial dysfunction and reactive oxygen species formation and cell detachment from the extracellular matrix. Methylglyoxal&#x2013;mediated damage is countered by glutathione-dependent metabolism by glyoxalase-1. It is not known, however, if glyoxalase-1 has stress responsive up-regulation to counter periods of high methylglyoxal concentration or dicarbonyl stress. We identified a functional antioxidant response element in the 5&#x2019;-untranslated region of exon-1 of the mammalian glyoxalase-1 gene. Transcription factor Nrf2 binds to this antioxidant response element increasing basal and inducible expression of glyoxalase 1. Activators of Nrf2 induced increased glyoxalase-1 mRNA, protein and activity. Increased expression of glyoxalase-1 decreased cellular and extracellular concentrations of methylglyoxal, methylglyoxal -derived protein adducts, mutagenesis and cell detachment. Hepatic, brain, heart, kidney and lung glyoxalase-1 mRNA and protein were decreased in Nrf2 (-/-) mice and urinary excretion of methylglyoxal protein and nucleotide adducts were increased <i>ca.</i> 2-fold. We conclude that dicarbonyl stress is countered by up-regulation of glyoxalase-1 in the Nrf2 stress responsive system, protecting protein and DNA from increased damage and preserving cell function.]]></description>
	<dc:creator>M Xue, N Rabbani, H Momiji, P Imbasi, M Anwar, N Kitteringham, K Park, T Souma, T MORIGUCHI, M Yamamoto, P J. Thornalley</dc:creator>
	<dc:date>2011-12-22T10:54:17Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111648</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-22</prism:publicationDate>
	<prism:section>BJ Metabolism</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111768">
	<title><![CDATA[Crystal structure of the Sox4 HMG/DNA complex suggests a mechanism for the positional interdependence in DNA recognition]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111768</link>
	<description><![CDATA[It has recently been proposed that the sequence preferences of DNA-binding transcription factors can be well described by models that include the positional interdependence of the nucleotides of the target sites. Such binding models allow for multiple motifs to be invoked, such as principal and secondary motifs differing at two or more nucleotide positions. However, the structural mechanisms underlying the accommodation of such variant motifs by TFs remain elusive. Here we present the crystal structure of the high-mobility group (HMG) domain of Sox4 bound to DNA. By comparing this structure with previously solved structures of Sox17 and Sox2 we observed subtle conformational differences at the DNA binding interface. Furthermore, using quantitative electrophoretic mobility shift assays (EMSAs) we validated the positional interdependence of two nucleotides and the presence of a secondary Sox motif in the affinity landscape of Sox4. These data suggest that a concerted rearrangement of two interface amino acids enables Sox4 to accommodate primary and secondary motifs. The structural adoptions lead to altered dinucleotide preferences that mutually reinforce each other. These analyses underline the complexity of the DNA recognition by TFs and provide an experimental validation for the conceptual framework of positional interdependence and secondary binding motifs.]]></description>
	<dc:creator>R Jauch, C Keow Leng Ng, K Narasimhan, P R Kolatkar</dc:creator>
	<dc:date>2011-12-19T14:39:29Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111768</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-19</prism:publicationDate>
	<prism:section>BJ Structure</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111284">
	<title><![CDATA[Functional analysis of membraneous Fo-a subunit of F1Fo-ATP synthase by in vitro protein synthesis]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111284</link>
	<description><![CDATA[F<sub>o</sub>-<i>a</i> subunit of F<sub>1</sub>F<sub>o</sub>-ATP synthase (F<sub>1</sub>F<sub>o</sub>) is a highly hydrophobic protein with five putative transmembrane helices and it plays a central role in H<sup>&#x002B;</sup>-translocation that is coupled with ATP synthesis/hydrolysis. Here, we show that F<sub>o</sub>-<i>a</i> subunit produced by the in vitro protease-free protein synthesis system (PURE system) is integrated into a preformed F<sub>o</sub>-<i>a</i>-less F<sub>1</sub>F<sub>o</sub> complex in the <em>Escherichia coli</em> membrane vesicles and in liposomes. The resulting F<sub>1</sub>F<sub>o</sub> has H<sup>&#x002B;</sup>-coupled ATP synthesis/hydrolysis activity that is approximately half of that of the native F<sub>1</sub>F<sub>o</sub>. By using this procedure, we analyzed five mutations of F<sub>1</sub>F<sub>o</sub>, where the conserved residues in F<sub>o</sub>-<i>a</i> subunit (N90, D112, R169, N173, and Q217) were individually replaced with alanine. All of the mutant F<sub>o</sub>-<i>a</i> subunits were successfully incorporated into F<sub>1</sub>F<sub>o</sub>, showing the advantage over conventional expression in <i>E. coli</i> by which three (N90A, D112A, and Q217A) mutant F<sub>o</sub>-<i>a</i> subunits were not found in F<sub>1</sub>F<sub>o</sub>. A mutant N173A retained full activity and mutants D112A and Q217A weak but detectable activity. No activity was observed for mutants of R169A, as reported, and N90A. N90 is located in the middle of putative second transmembrane helix and likely to play an important role in H<sup>&#x002B;</sup>-translocation. This work exemplifies that the PURE system provides an alternative approach when in vivo expression of membraneous components in protein complexes turns out to be difficult.]]></description>
	<dc:creator>Y Kuruma, T Suzuki, S Ono, M Yoshida, T Ueda</dc:creator>
	<dc:date>2011-12-14T12:07:26Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111284</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-14</prism:publicationDate>
	<prism:section>BJ Energy</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111739">
	<title><![CDATA[RCD1-DREB2A interaction in leaf senescence and stress responses in Arabidopsis thaliana]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111739</link>
	<description><![CDATA[Transcriptional regulation of gene expression is one major determinant of developmental control and stress adaptation in virtually all living organisms. In recent years numerous transcription factors controlling various aspects of plant life have been identified. The activity of transcription factors needs to be regulated to prevent unspecific, prolonged or inappropriate responses. The transcription factor DEHYDRATION-RESPONSIVE ELEMENT BINDING 2A (DREB2A) has been identified as one of the main regulators of drought and heat responses, and it is regulated through protein stability. Here we present evidence that the interaction with RADICAL-INDUCED CELL DEATH1 (RCD1) contributes to the control of DREB2A under a range of conditions. The interaction is mediated by a novel protein motif in DREB2A and a splice variant of <i>DREB2A</i> which lacks the interaction domain accumulates during heat stress and senescence. In addition RCD1 is rapidly degraded during heat stress, thus our results suggest that removal of RCD1 protein or the loss of the interaction domain in DREB2A appears to be required for proper DREB2A function under stress conditions.]]></description>
	<dc:creator>J P Vainonen, P Jaspers, M Wrzaczek, A Lamminm&#x00E4;ki, R A Reddy, L Vaahtera, M Brosch&#x00E9;, J Kangasj&#x00E4;rvi</dc:creator>
	<dc:date>2011-12-12T16:51:43Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111739</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-12</prism:publicationDate>
	<prism:section>BJ Plant</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111502">
	<title><![CDATA[The chromatin binding protein HMGN3 stimulates histone acetylation and transcription across the Glyt1 gene]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111502</link>
	<description><![CDATA[HMGNs are nucleosome-binding proteins that alter the pattern of histone modifications and modulate the binding of linker histones to chromatin. The HMGN3 family member exists as two splice forms, HMGN3a which is full length and HMGN3b which lacks the C-terminal regulatory domain. Here, we have used the <i>Glyt1</i> gene as a model system to investigate where HMGN proteins are bound across the locus <i>in vivo</i>, and to study how the two HMGN3 splice variants affect histone modifications and gene expression. We demonstrate that HMGN1, HMGN2, HMGN3a and HMGN3b are bound across the <i>Glyt1</i> gene locus and surrounding regions, and are not enriched more highly at the promoter or putative enhancer. We conclude that the peaks of H3K4me3 and H3K9ac at the active <i>Glyt1a</i> promoter do not play a major role in recruiting HMGN proteins. HMGN3a/b binding leads to increased H3K14 acetylation and stimulates <i>Glyt1a</i> expression, and but does not alter the levels of H3K4me3 or H3K9ac enrichment. Acetylation assays show that HMGN3a stimulates the ability of PCAF to acetylate nucleosomal H3 <i>in vitro</i>, whereas HMGN3b does not. We propose a model where HMGN3a/b&#x2013;stimulated H3K14 acetylation across the bodies of large genes like <i>Glyt1</i> can lead to more efficient transcription elongation and increased mRNA production.]]></description>
	<dc:creator>G Barkess, Y Postnikov, C D Campos, S Mishra, G Mohan, S Verma, M Bustin, K L West</dc:creator>
	<dc:date>2011-12-12T16:16:08Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111502</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-12</prism:publicationDate>
	<prism:section>BJ Gene</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111745">
	<title><![CDATA[A Cohesin-RAD21 Interactome]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111745</link>
	<description><![CDATA[The cohesin complex holds the sister chromatids together from S phase until the metaphase-to-anaphase transition and ensures both their proper cohesin and timely separation. In addition to its canonical function in chromosomal segregation, cohesion has been suggested by several lines of investigation in recent years to play additional roles in apoptosis, DNA damage response, transcriptional regulation, and hematopoiesis. To better understand the basis of the disparate cellular functions of cohesin in these various processes, we have characterized a comprehensive protein interactome of cohesin-RAD21 by using three independent approaches: yeast 2-hybrid (Y2H) screening, immunoprecipitation-coupled-mass spectrometry (IP-M) of cytoplasmic and nuclear extracts from MOLT-4 T lymphocytes in the presence and absence of etoposide induced apoptosis, and affinity-pull down assays of chromatographically purified nuclear extracts from proapoptotic MOLT-4 cells. Our analyses revealed 112 novel protein interactors of cohesin RAD21 that function in different cellular processes including mitosis, regulation of apoptosis, chromosome dynamics, replication, transcription regulation, RNA processing, DNA damage response, protein modification and degradation, and cytoskeleton and cell motility. Identification of cohesin interactors provides a framework for explaining the various non-canonical functions of the cohesin complex.]]></description>
	<dc:creator>A K Panigrahi, N Zhang, S K Otta, D Pati</dc:creator>
	<dc:date>2011-12-07T12:10:00Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111745</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-07</prism:publicationDate>
	<prism:section>BJ Cell</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111322">
	<title><![CDATA[Epidermal Growth Factor Induces Tumor Marker AKR1B10 Expression through Activator Protein-1 Signaling in Hepatocellular Carcinoma Cells]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111322</link>
	<description><![CDATA[<b>Synopsis</b>

Aldo-keto reductase1B10 (AKR1B10) is overexpressed in live and lung cancer and plays a critical role in tumor development and progression through promoting lipogenesis and eliminating cytotoxic carbonyls. AKR1B10 is a secretory protein and potential tumor marker. However, little is known about the regulatory mechanism of AKR1B10 expression. This study showed that AKR1B10 is induced by mitogens epidermal growth factor (EGF) and insulin through the activator protein-1 (AP-1) signaling pathway. In human hepatocellular carcinoma cells (HepG2 and Hep3B), EGF (50ng/ml) and insulin (10nM) stimulated endogenous AKR1B10 expression and promoter activity. In the AKR1B10 promoter, a putative AP-1 element was found at -222 to -212bp. Deletion or mutations of this AP-1 element abrogated the basal promoter activity and response to EGF and AP-1 proteins. This AP-1 element bound to nuclear proteins extracted from HepG2 cells, and this binding was stimulated by EGF and insulin in a dose-dependent manner. Chromatin immunoprecipitation showed that AP-1 proteins c-Fos and c-Jun were predominant factors bound to the AP-1 consensus, followed by JunD and then JunB. The same order was followed in the stimulation of endogenous AKR1B10 expression by AP-1 proteins. Furthermore, c-Fos shRNA and AP-1 inhibitors/antagonists (U0126 and Tanshinone IIA) inhibited the endogenous AKR1B10 expression and promoter activity in HepG2 cells cultured <i>in vitro</i> or inoculated subcutaneously in nude mice. U0126 also inhibited AKR1B10 expression induced by EGF. Together these data suggest that AKR1B10 is upregulated by EGF and insulin through the AP-1 mitogenic signaling and may be implicated in hepatocarcinogenesis.]]></description>
	<dc:creator>Z Liu, R Yan, A Al-salman, Y Shen, Y Bu, J Ma, D Luo, C Huang, Y Jiang, A Wilber, Y Mo, M Huang, Y Zhao, D Cao</dc:creator>
	<dc:date>2011-12-02T16:18:34Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111322</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-02</prism:publicationDate>
	<prism:section>BJ Signal</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111271">
	<title><![CDATA[Oligoamine Analogues in Combination with 2-Difluoromethylornithine (DFMO) Synergistically Induce Re-expression of Aberrantly Silenced Tumor Suppressor Genes]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111271</link>
	<description><![CDATA[Epigenetic gene silencing is an important mechanism in the initiation and progression of cancer. Abnormal DNA CpG island hypermethylation and histone modifications are involved in aberrant silencing of tumor suppressor genes. Lysine-specific demethylase 1 (LSD1) was the first enzyme identified to specifically demethylate lysine 4 of histone H3 (H3K4). Methylated H3K4 is an important mark associated with transcriptional activation. The flavin adenine dinucleotide binding, amine oxidase domain of LSD1 is homologous to two polyamine oxidases, spermine oxidase and N<sup>1</sup>-acetylpolyamine oxidase. We have demonstrated that long chain polyamine analogues, the oligoamines, are inhibitors of LSD1. Here we report the synergistic effects of specific oligoamines in combination with 2-difluoromethylornithine (DFMO), an inhibitor of ornithine decarboxylase, in human colorectal cancer cells. DFMO treatment depletes natural polyamines and increases the uptake of exogenous polyamines. The combination of oligoamines and DFMO results in a synergistic re-expression of aberrantly silenced tumor suppressor genes, including the secreted frizzled-related protein 2 (<i>SFRP2</i>) gene, which encodes a Wnt signaling pathway antagonist and plays an anti-tumorigenic role in colorectal cancer. The treatment-induced re-expression of <i>SFRP2</i> is associated with increased H3K4me2 in the gene promoter. The combination of LSD1-inhibiting oligoamines and DFMO represents a novel approach to epigenetic therapy of cancer.]]></description>
	<dc:creator>Y Wu, N Steinbergs, T Murray-Stewart, L J. Marton, R A Casero Jr.</dc:creator>
	<dc:date>2011-12-02T10:55:23Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111271</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-02</prism:publicationDate>
	<prism:section>BJ Disease</prism:section>
</item>

<item rdf:about="http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111517">
	<title><![CDATA[Up-regulated miR-17 promotes cell proliferation, tumor growth and cell cycle progression by targeting RND3 tumor suppressor gene in colorectal carcinoma]]></title>
	<link>http://www.biochemj.org/bj/imps/refer.htm?MSID=BJ20111517</link>
	<description><![CDATA[Emerging evidence indicates that the miR-17 family may have a causal role in human cancer tumorigenesis, but their specific effects on occurrence of colorectal carcinoma (CRC) are still poorly understood. In this study, we profiled CRC tissue samples by miRNA microarray and found that four members of the miR-17 family had higher expressions in CRC tissues than in normal tissues. This finding was further validated by qRT-PCR. Transfecting CRC cells with an inhibitor of miR-17 lowered their ability to proliferate and induced G<sub>0</sub>/G<sub>1</sub> arrest. We also confirmed that miR-17 exerted this function by directly targeting RND3 in vitro and that the expression of miR-17 was negatively correlated with that of RND3 in CRC tissues and CRC cells. Moreover, miR-17 inhibition led to tumor growth suppression and up-regulation of RND3 expression in a nude mouse xenograft model. RND3 expression was found significantly lower in CRC tissues than in normal tissues and adenomas, indicating RND3 may act as a tumor suppressor gene in CRC. In conclusion, our study suggests that miR-17 plays an important role in CRC carcinogenesis by targeting RND3 and may be a therapeutic agent for CRC.]]></description>
	<dc:creator>H Luo, J Zou, Z Dong, Q Zeng, D Wu, L Liu</dc:creator>
	<dc:date>2011-12-01T15:34:18Z</dc:date>
	<dc:identifier>doi:10.1042/BJ20111517</dc:identifier>
	<dc:publisher>Portland Press Limited</dc:publisher>
	<prism:publicationDate>2011-12-01</prism:publicationDate>
	<prism:section>BJ Disease</prism:section>
</item>

</rdf:RDF>

